Search

everythinglearnresearchcommunity

for

Search:↓

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

IL-18 levels are higher in hidradenitis suppurativa patients and may indicate disease severity.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

sPLA2-IIA increases growth in hair follicle stem cells and cancer cells, suggesting it could be targeted for hair growth and cancer treatment.

Alarmin cytokines are key in controlling skin immunity and inflammation.

Anti-IL-1 treatments might help with certain types of hair loss in people with high inflammation.

Inhibiting the PI3K/Akt pathway may help prevent radiation-induced liver injury.

IL-27 can prevent hair loss in alopecia areata.

FCO2 laser is a better treatment for alopecia areata than intralesional steroids.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Patients with severe active alopecia areata have lower CD200 expression and an imbalance in their immune system.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Intralesional triamcinolone acetonide is more effective but has a higher relapse rate than platelet-rich plasma for treating alopecia areata.

RXRα is crucial for proper immune response and links diet to immune function.

A specific RNA helps increase the growth of skin cells in Liaoning cashmere goats by working with a protein to boost a growth-related gene.

People with severe hair loss have higher levels of a protein called interleukin 17 in their blood.

The PIRL laser cuts tissue with less damage and scarring than traditional methods.

CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss.

Removing UBE2N from skin cells causes inflammation and immune response, which can be lessened with specific inhibitors.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

A new compound from Royoporus badius activates immune cells and induces inflammatory responses.

Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

Inhibiting PLA2 enzymes may help treat inflammatory skin diseases like psoriasis and dermatitis.

PLAU and SerpinB2 affect cell death differently in various forms of leprosy and could be targets for new treatments.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Certain immune system genes are linked to a higher risk of psoriasis and psoriatic arthritis, while others may offer protection.

Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.

Blocking IL-17a can improve age-related smell loss in mice.